Mark A. Velleca - 16 Aug 2022 Form 4 Insider Report for G1 Therapeutics, Inc.

Role
Director
Signature
/s/ James Stillman Hanson, attorney-in-fact
Issuer symbol
N/A
Transactions as of
16 Aug 2022
Net transactions value
-$979,704
Form type
4
Filing time
18 Aug 2022, 16:06:10 UTC
Previous filing
17 Jun 2022
Next filing
19 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $31,200 +80,000 +69% $0.3900* 196,000 16 Aug 2022 Direct
transaction GTHX Common Stock Sale $1,010,904 -80,000 -41% $12.64* 116,000 16 Aug 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Option (Right to Buy) Options Exercise $0 -80,000 -46% $0.000000 92,286 16 Aug 2022 Common Stock 80,000 $0.3900 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price represents the weighted average price with a low of $12.40 and a high of $13.02. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.
F3 All shares underlying this option have vested.